About Allena Pharmaceuticals (NASDAQ:ALNA)

Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.

Receive ALNA News and Ratings via Email

Sign-up to receive the latest news and ratings for ALNA and its competitors with MarketBeat's FREE daily newsletter.

What price target have analysts set for ALNA?

6 brokerages have issued twelve-month target prices for Allena Pharmaceuticals' shares. Their forecasts range from $21.00 to $61.00. On average, they expect Allena Pharmaceuticals' share price to reach $32.90 in the next year. View Analyst Ratings for Allena Pharmaceuticals.

What are Wall Street analysts saying about Allena Pharmaceuticals stock?

Here are some recent quotes from research analysts about Allena Pharmaceuticals stock:

1. According to Zacks Investment Research, "Allena Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders primarily in the United States. The companys product candidate includes ALLN-177 and ALLN-346 which are in clinical stages. Allena Pharmaceuticals, Inc. is headquartered in Newton, Massachusetts. " (5/11/2018)

2. Wedbush analysts commented, "We reiterate our Underperform rating and $37 price target post 3Q:17 and after speaking with management. We continue to see minimal value from Eagle’s pipeline and expect the company to acquire an asset." (12/18/2017)

When did Allena Pharmaceuticals IPO?

(ALNA) raised $80 million in an initial public offering on Thursday, November 2nd 2017. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

When did the company's lock-up period expire?

Allena Pharmaceuticals' lock-up period expired on Tuesday, May 1st. Allena Pharmaceuticals had issued 5,333,333 shares in its public offering on November 2nd. The total size of the offering was $74,666,662 based on an initial share price of $14.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the expiration of the lock-up period.

Has Allena Pharmaceuticals been receiving favorable news coverage?

News coverage about ALNA stock has been trending somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Allena Pharmaceuticals earned a news sentiment score of 0.02 on Accern's scale. They also assigned press coverage about the company an impact score of 43.77 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

ALNA stock was purchased by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Millennium Management LLC, Citadel Advisors LLC, Wells Fargo & Company MN and BlackRock Inc.. Company insiders that have bought Allena Pharmaceuticals stock in the last two years include Bessemer Venture Partners Vii and James N Topper. View Insider Buying and Selling for Allena Pharmaceuticals.

How do I buy shares of Allena Pharmaceuticals?

Shares of ALNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Allena Pharmaceuticals' stock price today?

One share of ALNA stock can currently be purchased for approximately $14.91.

How big of a company is Allena Pharmaceuticals?

Allena Pharmaceuticals has a market capitalization of $305.47 million. The company earns $-21,650,000.00 in net income (profit) each year or ($4.80) on an earnings per share basis. Allena Pharmaceuticals employs 34 workers across the globe.

How can I contact Allena Pharmaceuticals?

Allena Pharmaceuticals' mailing address is ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462. The company can be reached via phone at 617-467-4577.

MarketBeat Community Rating for Allena Pharmaceuticals (ALNA)

MarketBeat's community ratings are surveys of what our community members think about Allena Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALNA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

6 Wall Street analysts have issued ratings and price targets for Allena Pharmaceuticals in the last 12 months. Their average twelve-month price target is $32.90, suggesting that the stock has a possible upside of 120.66%. The high price target for ALNA is $61.00 and the low price target for ALNA is $21.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy."